

12/8

PATENT
ATTORNEY DOCKET NO.: TNX00-04
CUSTOMER NO: 26839

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**In Re the Application of:
FUNG, Michael, et al.**

Serial No.: 09/816,839

Filed: March 23, 2001

For: ANTI C2/C2a INHIBITORS OF
COMPLEMENT ACTIVATION

Group Art Unit: 1644

Examiner: A. M. DeCloux

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

AMENDMENT AND RESPONSE

In response to the Office Action dated November 18, 2002, Applicants request reconsideration of the application in view of the following amendments and remarks.

The period for response has been extended to March 18, 2003, by a request for extension of time and the payment of the appropriate fee. If any additional fees are due in connection with this response, please charge our deposit account 20-0087.

Please amend the application as follows:

IN THE SPECIFICATION:

Please replace the following paragraphs:

At Page 6, line 16:

One embodiment of the present invention includes an inhibitor molecule comprising a monoclonal antibody. The antibody may be chimeric, DEIMMUNIZED™ (described below), humanized or human antibody. Specifically, the monoclonal antibody may be the monoclonal antibody designated 175-62.